Ethical Perspectives on Translational Pharmacogenetic Research Involving Children

Pediatric Drugs

Volumn 17, Issue 1, 2015, Pages 91-95

  Madadi, Parvaz ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHILD; COUNSELING; DRUG SAFETY; HEALTH CARE; HUMAN; INTERPERSONAL COMMUNICATION; PHARMACOGENETICS; PRIORITY JOURNAL; RESEARCH ETHICS; REVIEW; TRANSLATIONAL RESEARCH; ETHICS; MEDICAL RESEARCH; PEDIATRICS;

BIOMEDICAL RESEARCH; CHILD; HUMANS; PEDIATRICS; PHARMACOGENETICS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84921889893     PISSN: 11745878     EISSN: 11792019     Source Type: Journal    
DOI: 10.1007/s40272-014-0111-3     Document Type: Review

References (35)

1. Crews KR, Cross SJ, McCormick JN, Baker DK, Molinelli AR, Mullins R, Relling MV, Hoffman JM. Development and implementation of a pharmacist-managed clinical pharmacogenetics service. Am J Health Syst Pharm. 2011;68(2):143–50.
2. St. Jude’s Children’s Research Hospital. Non-therapeutic protocol PG4KDS: clinical implementation of pharmacogenetics. http://www.stjude.org/pg4kds. Accessed 6 Aug 2014.
3. O’Donnell PH, Danahey K, Jacobs M, Wadhwa NR, Yuen S, Bush A, Sacro Y, Sorrentino MJ, Siegler M, Harper W, Warrick A, Das S, Saner D, Corless CL, Ratain MJ. Adoption of a clinical pharmacogenomics implementation program during outpatient care—initial results of the University of Chicago “1,200 patients project”. Am J Med Genet C Semin Med Genet. 2014;166C(1):68–75.
4. Cincinnati Children’s Hospital. Genetic pharmacology service. http://www.cincinnatichildrens.org/service/g/genetic-pharmacology/default/. Accessed 16 Nov 2014.
5. Institute of Medicine (US). Roundtable on translating genomic-based research for health innovations in service delivery in the age of genomics. 3, New Models for Service Delivery. Workshop summary, Washington, DF: Academies Press; 2009. http://www.ncbi.nlm.nih.gov/books/NBK26398/. Accessed 16 Nov2014.
6. United States Food and Drug Administration. Table of pharmacogenomic biomarkers in drug labels. 2014. www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/ucm083378.htm. Accessed 5 Aug 2014.
7. Knoppers BM, Joly Y, Simard J, Durocher F. The emergence of an ethical duty to disclose genetic research results: international perspectives. Eur J Hum Genet. 2006;14(11):1170–8.
8. Madadi P, Koren G. Pharmacogenetic insights into codeine analgesia: implications to pediatric codeine use. Pharmacogenomics. 2008;9(9):1267–84.
9. Ciszkowski C, Madadi P, Phillips MS, Lauwers AE, Koren G. Codeine, ultrarapid-metabolism genotype, and postoperative death. N Engl J Med. 2009;361(8):827–8.
10. Biss TT, Avery PJ, Brandão LR, Chalmers EA, Williams MD, Grainger JD, Leathart JB, Hanley JP, Daly AK, Kamali F. VKORC1 and CYP2C9 genotype and patient characteristics explain a large proportion of the variability in warfarin dose requirement among children. Blood. 2012;119(3):868–73.
11. Jarvik GP, Amendola LM, Berg JS, Brothers K, Clayton EW, Chung W, Evans BJ, Evans JP, Fullerton SM, Gallego CJ, Garrison NA, Gray SW, Holm IA, Kullo IJ, Lehmann LS, McCarty C, Prows CA, Rehm HL, Sharp RR, Salama J, Sanderson S, Van Driest SL, Williams MS, Wolf SM, Wolf WA, eMERGE Act-ROR Committee and CERC Committee, CSER Act-ROR Working Group, Burke W. Return of genomic results to research participants: the floor, the ceiling, and the choices in between. Am J Hum Genet. 2014;94(6):818–26.
12. Knoppers BM, Avard D, Sénécal K, Zawati MH. P3G International Paediatrics Platform Members. Return of whole-genome sequencing results in paediatric research: a statement of the P3G international paediatrics platform. Eur J Hum Genet. 2014;22(1):3–5.
13. Haga SB, Burke W. Practical ethics: establishing a pathway to benefit for complex pharmacogenomic tests. Clin Pharmacol Ther. 2011;90(1):25–7.
14. Frueh FW. Back to the future: why randomized controlled trials cannot be the answer to pharmacogenomics and personalized medicine. Pharmacogenomics. 2009;10(7):1077–81.
15. Mrazek DA, Lerman C. Facilitating clinical implementation of pharmacogenomics. JAMA. 2011;306(3):304–5.
16. Burnett HF, Tanoshima R, Chandranipapongse W, Madadi P, Ito S, Ungar WJ. Testing for thiopurine methyltransferase status for safe and effective thiopurine administration: a systematic review of clinical guidance documents. Pharmacogenomics J. 2014;14(6):493–502.
17. Green RC, Berg JS, Grody WW, Kalia SS, Korf BR, Martin CL, McGuire AL, Nussbaum RL, O’Daniel JM, Ormond KE, Rehm HL, Watson MS, Williams MS, Biesecker LG, American College of Medical Genetics and Genomics. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med. 2013;15(7):565–74.
18. American College of Medical Genetics and Genomics. Incidental findings in clinical genomics: a clarification. Genet Med. 2013;15(8):664–6.
19. McPherson J, Jirjis JN, Roden DM. Operational implementation of prospective genotyping for personalized medicine: the design of the Vanderbilt PREDICT project. Clin Pharmacol Ther. 2012;92(1):87–95.
20. Mesika Y, Lee BC, Tsimerman Y, Roitman H, Park HK. Using pharmacogenetics knowledge to increase accuracy of alerts for adverse drug events. Stud Health Technol Inform. 2011;169:569–73.
21. Avard D, Sénécal K, Madadi P, Sinnett D. Pediatric research and the return of individual research results. J Law Med Ethics. 2011;39(4):593–604.
22. Patenaude AF, Basili L, Fairclough DL, Li FP. Attitudes of 47 mothers of pediatric oncology patients toward genetic testing for cancer predisposition. J Clin Oncol. 1996;14(2):415–21.
23. Madadi P, Ciszkowski C, Gaedigk A, Leeder JS, Teitelbaum R, Chitayat D, Koren G. Genetic transmission of cytochrome P450 2D6 (CYP2D6) ultrarapid metabolism: implications for breastfeeding women taking codeine. Curr Drug Saf. 2011;6(1):36–9.
24. Haga SB, Mills R, Bosworth H. Striking a balance in communicating pharmacogenetic test results: promoting comprehension and minimizing adverse psychological and behavioral response. Patient Educ Couns. 2014;97(1):10–5.
25. Mills R, Voora D, Peyser B, Haga SB. Delivering pharmacogenetic testing in a primary care setting. Pharmgenomics Pers Med. 2013;18(6):105–12.
26. Madadi P, Joly Y, Avard D, Chitayat DC, Smith MA, Ross CJ, Carleton BC, Hayden MR, Koren G. Communicating pharmacogenetic research results to breastfeeding mothers taking codeine: a pilot study of perceptions and benefits. Clin Pharmacol Ther. 2010;88(6):792–5.
27. Madadi P, Joly Y, Avard D, Chitayat DC, Smith MA, D Ross CJ, Carleton BC, Hayden MR, Koren G. The communication of pharmacogenetic research results: participants weigh in on their informational needs in a pilot study. J Popul Ther Clin Pharmacol. 2011;18:e152–5.
28. Walfisch A, Sermer C, Matok I, Einarson A, Koren G. Perception of teratogenic risk and the rated likelihood of pregnancy termination: association with maternal depression. Can J Psychiatry. 2011;56(12):761–7.
29. Ali-Khan SE, Daar AS, Shuman C, Ray PN, Scherer SW. Whole genome scanning: resolving clinical diagnosis and management amidst complex data. Pediatr Res. 2009;66(4):357–63.
30. Haddy CA, Ward HM, Angley MT, McKinnon RA. Consumers’ views of pharmacogenetics—a qualitative study. Res Social Adm Pharm. 2010;6(3):221–31.
31. Fargher EA, Eddy C, Newman W, Qasim F, Tricker K, Elliott RA, Payne K. Patients’ and healthcare professionals’ views on pharmacogenetic testing and its future delivery in the NHS. Pharmacogenomics. 2007;8(11):1511–9.
32. Haga SB, O’Daniel JM, Tindall GM, Lipkus IR, Agans R. Survey of US public attitudes toward pharmacogenetic testing. Pharmacogenomics J. 2012;12(3):197–204.
33. Stanek EJ, Sanders CL, Taber KA, Khalid M, Patel A, Verbrugge RR, Agatep BC, Aubert RE, Epstein RS, Frueh FW. Adoption of pharmacogenomic testing by US physicians: results of a nationwide survey. Clin Pharmacol Ther. 2012;91(3):450–8.
34. Haga SB, Burke W, Ginsburg GS, Mills R, Agans R. Primary care physicians’ knowledge of and experience with pharmacogenetic testing. Clin Genet. 2012;82(4):388–94.
35. Alexander KM, Divine HS, Hanna CR, Gokun Y, Freeman PR. Implementation of personalized medicine services in community pharmacies: perceptions of independent community pharmacists. J Am Pharm Assoc (2003). 2014;54(5):510–7.